(Total Views: 136)
Posted On: 09/18/2019 1:31:24 PM
Post# of 7852
$ISWH this is a monumental turnaround story in terms of tangible financial performance. The growth on the top-line is in place. The EBITDA profitability is now in place as well. And now, it looks an awful lot like we are about to see the extra growth engine of multi-segment performance start to kick into gear as CBD sales ramp back up.
To give you some sense of how this could impact the picture, if we look back to the company’s projections posted in January, which included the CBD segment working at full volume, the sales estimates and guidance would add up to at least a 100% jump in revenues next quarter, and possibly much more. If that is coming in the context of EBITDA profitability, then this would not at all suggest the current pricing of shares is even remotely reasonable. Ramping Up: Sub-Penny $ISWH to Resume #CBD Sales After Turning Profitable https://www.journaltranscript.com/2019/09/ram...rofitable/
$SRNA $PHOT $MJNE $BILZ $PHIL $ASTI $HBRM $TCEL $CELZ $ETFM $AITX $LAHO $HIHI $RNVA $LIBE $MAXD $HEMP $IGEX $ERBB $BRKK $DGTW $TGRO $DSCR $MMEX $NYXO $DPLS $PACV $NTRR $XREG
To give you some sense of how this could impact the picture, if we look back to the company’s projections posted in January, which included the CBD segment working at full volume, the sales estimates and guidance would add up to at least a 100% jump in revenues next quarter, and possibly much more. If that is coming in the context of EBITDA profitability, then this would not at all suggest the current pricing of shares is even remotely reasonable. Ramping Up: Sub-Penny $ISWH to Resume #CBD Sales After Turning Profitable https://www.journaltranscript.com/2019/09/ram...rofitable/
$SRNA $PHOT $MJNE $BILZ $PHIL $ASTI $HBRM $TCEL $CELZ $ETFM $AITX $LAHO $HIHI $RNVA $LIBE $MAXD $HEMP $IGEX $ERBB $BRKK $DGTW $TGRO $DSCR $MMEX $NYXO $DPLS $PACV $NTRR $XREG
(0)
(0)
